Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of Injected Peanut Immunotherapy for Persistent Peanut Allergy
NCT04974970Phase 2Terminated
- Start
- Apr 2019
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peanut allergen extract in peanut allergy. Primary endpoint: Result (positive or negative) and cumulative reaction threshold at 3 months peanut oral food challenge (OFC). Started Apr 2019; status: terminated.
02
Drugs
peanut allergen extract
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT04974970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04974970.